Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities
Evofem Announces Closing Of Merger With Neothetics
OCON Medical announces its new successful round of financing & arrival of Chemo Group as shareholder
Neothetics, Inc. and Evofem Biosciences, Inc. Announce Merger Agreement to Create Women’s Health Company
Syndax Announces $25 Million Registered Direct Offering of Common Stock
Marinus Pharmaceuticals Announces closing of Public Offering of Common Stock and full exercise of underwriter's option to purchase additional shares
NovaMedica began construction of a pharmaceutical plant in the Kaluga regions
Syndax Announces Proposed Public Offering of Common Stock
NovaMedica launched Technology Center to develop innovative drugs
Epic Sciences Announces Completion of $40 Million Series D Financing
Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder
Atlas Genetics Raises $35m in Series D Fundraising
Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index
Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome
Allergan Successfully Completes Tobira Therapeutics Acquisition
Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH
NovaMedica, our portfolio company, and Pfizer announce a strategic partnership in Russia
Syndax Expands Pipeline With Exclusive Worldwide License Agreement for UCB's Colony Stimulating Factor 1 Receptor (CSF-1R) Antibody Program
Genomic Health and Epic Sciences Announce Strategic Collaboration to Deliver Novel AR-V7 Liquid Biopsy Test to Predict Treatment Response in Metastatic Prostate Cancer
Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus
Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion
Clearside Biomedical, Inc. Completes $20 Million Series C Financing
NovaMedica is starting construction of R&D Center for drug development using nanotechnologies
Marinus Pharmaceuticals Announces Public Offering of Common Stock
First US Commercial Appointment - Atlas Genetics appoints Keith Stauffer as VP Sales & Marketing
Our portfolio company Transcend Medical Submits Final Module of FDA Premarket Approval Application for the CyPass® Glaucoma Micro-Stent
Our portfolio company Marinus Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA for Ganaxolone in Focal Onset Seizures
Atlas Genetics Ltd: Grant of Key US Patent
Our portfolio company Syndax Raises $80 Million In Series C Financing
Celtaxsys Secures $45M in Capital to Fund Novel Anti-inflammatory Phase 2 Programs in Cystic Fibrosis and Acne
Atlas Genetics reels in $20M in Series C round for rapid infectious disease tests
Clearside Biomedical, Inc. Completes $16 Million Series B Financing
Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine
Miramar Labs Secures $10 Million in Series D Funding
NovaDigm Therapeutics Raises $14M Series B to Support Phase 2 Trial of NDV-3 Vaccine
RusnanoMedInvest, Domain Associates and investor syndicate back ReVision Optics vision correction technology with $55 mln investment.
RusnanoMedInvest and Domain Associates to invest $93m in development of three next-generation pharmaceuticals.
Vladimir Gurdus: In order to foster the development of an innovative pharmaceuticals sector in Russia, we need the support of a globally competitive network of venture investors in the sector here in Russia.
Leonid Melamed: Isolated oases of narrowly focused innovation in life sciences are not the way forward for Russia and represent a temporary fix at best – what is needed to drive truly transformational change are fully-integrated life sciences innovation clusters supported by an ecosystem of research and development, finance and other key success factors and specialized skill sets.
Announcement of the first RusnanoMedInvest transaction - acquisition of shares of CoDa Therapeutics, Inc. (USA. CoDa is developing Nexagon, an innovative chronic wound healing solution with targeted applications in diabetic foot ulcers, venous leg ulcers and other chronic wound pathologies.
RUSNANO JSC and U.S. venture fund Domain Associates announced the launch of their joint investment program, as a result of which RusnanoMedInvestwas founded.
The agreement between RUSNANO JSC and Team Drive on the management and operation of the RusnanoMedInvest investment program was signed.
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.